Brazil’s SUS to Add Three Lung Cancer Drugs by October

Brazil’s public health system (SUS) will begin offering three new medications for lung cancer treatment in October, according to an announcement from the country’s health ministry, as reported by www.gov.br.

The move, first publicized on August 31, 2026, marks an expansion of oncology care within the national health service. The three drugs are classified as high-cost treatments, according to Brazilian news outlet VEJA, which also covered the announcement.

The health ministry’s statement, carried by www.gov.br, did not specify the names of the medications or the exact patient populations eligible for the new treatments. However, multiple Brazilian outlets, including g1.globo.com and Correio Braziliense, confirmed that the drugs will be added to SUS’s official list of covered medicines, a step that ensures public funding and distribution.

The decision follows a broader effort to improve access to advanced cancer therapies in Brazil, where lung cancer remains one of the leading causes of cancer-related deaths. The inclusion of these drugs in the SUS formulary is expected to reduce out-of-pocket costs for patients who previously had limited options within the public system.

sus

Campo Grande News also reported on the upcoming availability, noting that the rollout is scheduled to begin in October. The health ministry has not yet released a detailed implementation timeline beyond that initial date.

What to watch next: The ministry is expected to publish the official list of the three drugs and their clinical indications, which will clarify which patients can access the new treatments under SUS.